Drug interactions
Glecaprevir / pibrentasvir + Regorafenib
Severity: Moderate
Glecaprevir / pibrentasvir and Regorafenib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Regorafenib inhibits BCRP and may increase exposure to glecaprevir and pibrentasvir, which are BCRP substrates. This could increase hepatic adverse effects, particularly in patients with liver impairment.
What this interaction means in plain words
Glecaprevir / pibrentasvir and Regorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Regorafenib inhibits BCRP-mediated efflux of glecaprevir and pibrentasvir.
What to do
Monitor liver function tests during co-administration. Watch for hepatotoxicity and any signs of hepatic decompensation.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Glecaprevir / pibrentasvir and Regorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Regorafenib
Frequently asked questions
Can I take Glecaprevir / pibrentasvir with Regorafenib?
MediHelp rates the interaction as moderate. Glecaprevir / pibrentasvir and Regorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Regorafenib inhibits BCRP and may increase exposure to glecaprevir and pibrentasvir, which are BCRP substrates. This could increase hepatic adverse effects, particularly in patients with liver impairment.
How serious is the interaction between Glecaprevir / pibrentasvir and Regorafenib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor liver function tests during co-administration. Watch for hepatotoxicity and any signs of hepatic decompensation.
What other medicines interact with Regorafenib?
MediHelp also lists interactions of Regorafenib with, for example, Apalutamide, Atazanavir, Carbamazepine. The full list is on the Regorafenib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
